Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Frankel

Showing results (51-60 of 147) with videos related to

Pageof 15
Sort By:
Anticancer Research|March 25, 2010
Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumorsJoseph Chao, G Thomas Budd, Peiguo Chu, et al.
Cancers|February 11, 2023
Mechanism-Driven and Clinically Focused Development of Botanical Foods as Multitarget Anticancer Medicine: Collective Perspectives and Insights from Preclinical Studies, IND Applications and Early-Phase Clinical TrialsXiaoqiang Wang, Yin S Chan, Kelly Wong, et al.
Stem Cells International|May 8, 2018
Early Changes in Tumor Perfusion from T1-Weighted Dynamic Contrast-Enhanced MRI following Neural Stem Cell-Mediated Therapy of Recurrent High-Grade Glioma Correlate with Overall SurvivalPrativa Sahoo, Paul Frankel, Julie Ressler, et al.
Cancer Research Communications|November 30, 2023
Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian CancerFerdynand J Kos, Paul Frankel, Mihaela Cristea, et al.
British Journal of Haematology|September 22, 2016
A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium StudyMark H Kirschbaum, Paul Frankel, Timothy W Synold, et al.
International Journal of Clinical Oncology|March 25, 2011
A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinomaDerek Shek, Jeff Longmate, David I Quinn, et al.
Cancer|May 20, 2015
A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus-induced prostate-specific antigen responsesPrzemyslaw Twardowski, Noriko Kanaya, Paul Frankel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2011
Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal originAhmad A Tarhini, Paul Frankel, Kim A Margolin, et al.
Anticancer Research|August 8, 2009
Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcomaAshkan Lashkari, Warren A Chow, Frances Valdes, et al.
Clinical Genitourinary Cancer|October 16, 2012
Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivorsSumanta K Pal, Jonathan Yamzon, Virginia Sun, et al.
Pageof 15

Showing results (51-60 of 147) with videos related to

Sort By:
Pageof 15
Anticancer Research|March 25, 2010
Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumorsJoseph Chao, G Thomas Budd, Peiguo Chu, et al.
Cancers|February 11, 2023
Mechanism-Driven and Clinically Focused Development of Botanical Foods as Multitarget Anticancer Medicine: Collective Perspectives and Insights from Preclinical Studies, IND Applications and Early-Phase Clinical TrialsXiaoqiang Wang, Yin S Chan, Kelly Wong, et al.
Stem Cells International|May 8, 2018
Early Changes in Tumor Perfusion from T1-Weighted Dynamic Contrast-Enhanced MRI following Neural Stem Cell-Mediated Therapy of Recurrent High-Grade Glioma Correlate with Overall SurvivalPrativa Sahoo, Paul Frankel, Julie Ressler, et al.
Cancer Research Communications|November 30, 2023
Immunologic Signatures of Peripheral Blood T Cells Reveal the Outcome of p53MVA Vaccine and Pembrolizumab Treatment in Patients with Advanced Ovarian CancerFerdynand J Kos, Paul Frankel, Mihaela Cristea, et al.
British Journal of Haematology|September 22, 2016
A phase II study of vascular endothelial growth factor trap (Aflibercept, NSC 724770) in patients with myelodysplastic syndrome: a California Cancer Consortium StudyMark H Kirschbaum, Paul Frankel, Timothy W Synold, et al.
International Journal of Clinical Oncology|March 25, 2011
A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinomaDerek Shek, Jeff Longmate, David I Quinn, et al.
Cancer|May 20, 2015
A phase I trial of mushroom powder in patients with biochemically recurrent prostate cancer: Roles of cytokines and myeloid-derived suppressor cells for Agaricus bisporus-induced prostate-specific antigen responsesPrzemyslaw Twardowski, Noriko Kanaya, Paul Frankel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 2, 2011
Aflibercept (VEGF Trap) in inoperable stage III or stage iv melanoma of cutaneous or uveal originAhmad A Tarhini, Paul Frankel, Kim A Margolin, et al.
Anticancer Research|August 8, 2009
Tandem high-dose chemotherapy followed by autologous transplantation in patients with locally advanced or metastatic sarcomaAshkan Lashkari, Warren A Chow, Frances Valdes, et al.
Clinical Genitourinary Cancer|October 16, 2012
Paclitaxel-based high-dose chemotherapy with autologous stem cell rescue for relapsed germ cell tumor: clinical outcome and quality of life in long-term survivorsSumanta K Pal, Jonathan Yamzon, Virginia Sun, et al.
Pageof 15